Nikitha Murthy

Nikitha Murthy

Auto-generated profile, based on publicly available information

Nikitha Murthy

Department of Cardiology, Department of Medicine, Loma Linda University Health, Loma Linda, California, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 August 2025 in Methodist DeBakey Cardiovascular Journal
Verified
Journal Article
Open access
PDF file
NMNikitha M. Murthy
Nikitha M. Murthy
TYThomas T. Yoo
Thomas T. Yoo
ASAlyssa Mariah Sanchez
Alyssa Mariah Sanchez
MCMayur Chhitu
Mayur Chhitu
DADmitry Abramov
Dmitry Abramov
PPPurvi Parwani
Purvi Parwani
Despite medical advances and increased perioperative testing, mortality and cardiovascular complications of noncardiac surgery (NCS) have hardly declined since the early 2000s. Studies demonstrate a disproportionate overutilization of preoperative diagnostic testing with a concurrent underutilization of interventions that have been shown to meaningfully modify mortality. Consequently, there has been a paradigm shift in the approach to perioperative testing. Current thinking advocates for a more judicious and individualized approach—that is, reserving noninvasive testing for select cases at highest risk of periprocedural cardiovascular events, where it may more effectively alter management. Thus, this review provides an update of the latest evidence-based recommendations on preoperative diagnostic assessment of patients with cardiovascular risk factors undergoing NCS, proposes a framework that can be referenced when approaching such a patient in clinical practice, and highlights areas that need more data to guide decision-making in clinical practice.

1 May 2026 in JACC: Advances
Verified
Journal Article
Open access
RSRamy Sedhom
Ramy Sedhom
NMNikitha Murthy
Nikitha Murthy
MMMichael Megaly
Michael Megaly
ABAnju Bhardwaj
Anju Bhardwaj
OKOfer Kobo
Ofer Kobo
DADmitry Abramov
Dmitry Abramov
There is a gap in current research looking at differences between diabetes subtypes in the setting of cardiogenic shock (CS). The authors sought to evaluate differences in characteristics, management, and outcomes between patients with no diabetes mellitus (DM), type 1 DM (T1DM), and type 2 DM (T2DM) admitted with CS. The National Readmissions Database was utilized to identify patients between 2016 and 2021 with any discharge diagnosis of CS. The cohort was divided into 3 groups: CS without DM, CS with T1DM, and CS with T2DM. The primary outcomes were all-cause in-hospital mortality and 30-day readmissions. A total of 1,073,340 patients hospitalized with CS were identified during the study period, of which 644,768 (60.0%) had no DM, 10,423 (1.0%) had T1DM, and 418,149 (39.0%) had T2DM. Those with T1DM were more likely to present with CS due to acute myocardial infarction and undergo invasive evaluation with left heart catheterization compared to those with T2DM and no DM. In-hospital mortality was higher among those with T1DM (adjusted OR: 1.16; 95% CI: 1.09-1.24) and T2DM (adjusted OR: 1.08; 95% CI: 1.07-1.10) compared to those without DM, and both groups were more likely to be readmitted within 30 days. Among patients with CS from acute myocardial infarction, in-hospital mortality was similar between patients with T1DM and no DM, but higher in those with T2DM. Patients with DM, particularly T1DM, who present with CS represent a high-risk cohort with greater in-hospital mortality and higher readmission rates compared to patients without DM.

21 February 2026 in Palliative Medicine
Verified
Journal Article
Closed access
NMNikitha Murthy
Nikitha Murthy
RSRamy Sedhom
Ramy Sedhom
PPPurvi Parwani
Purvi Parwani
MPMegan Pelter
Megan Pelter
LSLiset Stoletniy
Liset Stoletniy
DADmitry Abramov
Dmitry Abramov
Background: Heart failure hospitalizations are linked to high morbidity and mortality. Palliative care consultation may improve symptom management and quality of life yet remains underutilized. Aim: To evaluate recent trends in palliative care consultation and do-not-resuscitate status among heart failure hospitalizations, as well as associated outcomes. Design: We conducted a retrospective cohort study using the United States National Readmission Database from 2016 through 2022. Hospitalizations with a discharge diagnosis of heart failure were categorized into four groups: palliative care consultation only, do-not-resuscitate status only, both palliative care consultation and do-not-resuscitate status, or neither. Setting/participants: A total of 7,533,995 weighted hospitalizations with a discharge diagnosis of heart failure were identified. Of these, 281,720 (3.7%) included both palliative care consultation and do-not-resuscitate status, 124,236 (1.6%) utilized palliative care consultation only, 862,535 (11.4%) included do-not-resuscitate status only, and 6,265,504 (83.2%) included neither. Results: Utilization of palliative care consultation (4.7%–5.9%) and do-not-resuscitate status (12.4%–16.6%) increased over the study period. In unadjusted analyses, all-cause in-hospital mortality was highest in the both palliative care consultation/do-not-resuscitate status group (31%). Thirty-day unplanned readmission rate was highest in the no palliative care consultation/do-not-resuscitate status group (22.7%). Notably, 50.6% of heart failure admissions who died during hospitalization did not receive a palliative care consultation. Conclusions: While palliative care and do-not-resuscitate use among heart failure hospitalizations have increased, they remain low. Over half of those who die during a heart failure admission do not receive palliative care consultation, underscoring missed opportunities to optimize end-of-life care.

1 January 2026 in Case Reports in Cardiology
Verified
Journal Article
Open access
PDF file
NMNikitha Murthy
Nikitha Murthy
BDBrian Diep
Brian Diep
JEJonathan Evans
Jonathan Evans
DADmitry Abramov
Dmitry Abramov
DTDiane Tran
Diane Tran
Background: Hypertrophic cardiomyopathy (HCM) is a myocardial disorder characterized by hypertrophy of the left ventricle that can lead to significant symptoms, particularly with exercise. For patients with HCM who demonstrate obstructive physiology, the first‐in‐class targeted cardiac specific myosin inhibitor, mavacamten, has been found to reduce the degree of obstruction as well as symptoms. Case Summary: We present a patient with symptomatic HCM who had no left ventricular outflow tract obstruction (LVOTO) at rest but demonstrated obstruction on treadmill stress echocardiography. She had symptomatic improvement after treatment with mavacamten. Discussion: Patients with symptomatic HCM who do not demonstrate elevated resting gradients may benefit from evaluation of exercise‐induced gradients to diagnose obstructive HCM and guide initiation of targeted therapy with mavacamten. Take Home Message: Mavacamten may be safe and effective in patients who demonstrate LVOTO only upon provocation with exercise.

29 July 2026 in Clinical Journal of the American Society of Nephrology
Verified
Journal Article
Closed access
NMNikitha Murthy
Nikitha Murthy
ASAlyssa Mariah Sanchez
Alyssa Mariah Sanchez
JRJanani Rangaswami
Janani Rangaswami
SKSadiya S. Khan
Sadiya S. Khan
RMRoy O Mathew
Roy O Mathew
Key Points: The Predicting Risk of Cardiovascular Disease EVENTs equations optimize risk prediction in the modern era of increasing cardiovascular kidney metabolic disease prevalence. Risk prediction is most helpful to intensify therapy in those with less advanced kidney disease. In those with advanced kidney disease, risk indices provide little utility beyond biomarkers alone such as eGFR and albuminuria. Background: Cardiovascular kidney metabolic syndrome is a growing public health problem and leading cause of cardiovascular mortality. We evaluated model performance of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) equations in a large single health system population in patients with CKD and across strata of kidney function and compared findings where applicable to those of the pooled cohort equations (PCE). Methods: Veterans with eGFR measurements were divided into three groups: eGFR ≥60, eGFR 30–59, and eGFR 15–29. We assessed the base PREVENT equations for total cardiovascular disease (CVD), atherosclerotic CVD (ASCVD), and heart failure as well as add-on equations using albuminuria. Accuracy of equations was assessed with c-index as a measure of discrimination and calibration curve slopes as a measure of calibration. Results: Overall c-index was 0.651 for PREVENT-CVD, 0.633 for PREVENT-ASCVD, and 0.673 for PREVENT-heart failure. Discrimination of PREVENT-ASCVD was modestly greater than that of PCE (0.633 versus 0.629, respectively). For all three base PREVENT equations, discrimination declined with advancing kidney disease. Overall calibration slopes for the PREVENT equations ranged from 0.78 to 1.27. PREVENT-ASCVD had superior calibration compared to PCE with a calibration slope of 1.27 and 0.53, respectively. In those with urine albumin to creatinine ratio (UACR) measurements, discrimination of UACR add-on equations improved from base equations in those with less advanced kidney disease (c-index 0.624 for PREVENT-CVD UACR versus 0.607 for PREVENT-CVD base equation in those with eGFR ≥60, and c-index 0.586 for PREVENT-CVD UACR versus 0.563 for PREVENT-CVD base equation in those with eGFR 30–59). This trend was similar for the PREVENT-ASCVD and PREVENT-heart failure UACR add-on equations. Conclusions: In a CKD population, the PREVENT equations perform best in those less advanced stages of CKD and cardiovascular kidney metabolic, presenting an opportunity to apply disease-preventing and disease-modifying therapeutics in a timely manner. Podcast: This article contains a podcast at https://dts.podtrac.com/redirect.mpr/www.asn-online.org/media/podcast/CJASN/2026_10_30_CJASNOct.21.10.1030.mp3